Clinical Trial Update: GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for GB-5267 in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• GB-5267

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Platinum-resistant Ovarian Cancer | Phase 1 | Status: NOT_YET_RECRUITING